Neuro3d Initiates Phase I Trials with ND7001, a New Mechanism Antidepressant and Anxiolytic Compound
Initially, a double-blind, placebo-controlled, single, dose-escalation study will be conducted to investigate safety, tolerability and pharmacokinetics. Thereafter, a multiple-dose study will be conducted which will also include qEEG recordings to provide evidence of CNS effects and active dose range.
"ND7001 is the first drug of its kind to enter clinical development," noted Cesare Mondadori, CSO of Neuro3d. "The drug acts via a new mechanism and is well tolerated in preclinical studies. Our studies in animals show that ND7001 not only meets the criteria of an antidepressant but also of an anxiolytic compound."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.